NCT03733353View on ClinicalTrials.gov

A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

November 19, 2018

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions
PsoriasisAtopic Dermatitis
Interventions
DRUG

EDP1815

EDP1815 is an orally administered monoclonal microbial

DRUG

Placebo oral capsule

Placebo

DRUG

Placebo oral tablet

Placebo

Trial Locations (9)

Unknown

UK-8, Barnsley

UK-7, Blackpool

UK-3, Cannock

UK-4, Leeds

UK-5, Liverpool

UK-1, London

UK-2, Manchester

UK-6, Manchester

UK-9, Stockton-on-Tees

Sponsors
All Listed Sponsors
lead

Evelo Biosciences, Inc.

INDUSTRY

NCT03733353 - A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis | Biotech Hunter | Biotech Hunter